Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook – CNBC

Lead

On Feb. 3, 2026, Pfizer reported fourth-quarter results that topped Wall Street estimates even as demand for its Covid vaccine and antiviral Paxlovid continued to fall. The company posted adjusted earnings per share of $0.66 and revenue of $17.56 billion, beating consensus. Management reiterated a conservative 2026 outlook and highlighted longer-term investments, including the $10 billion Metsera acquisition and planned cost reductions. The mixed report eased near-term investor concerns about sales erosion but left questions about growth drivers beyond Covid-era products.

Key takeaways

• Pfizer reported adjusted EPS of $0.66 for Q4, above the LSEG analyst consensus of $0.57.
• Q4 revenue was $17.56 billion, versus estimates of $16.95 billion and roughly 1% lower than Q4 2024.
• The company booked a GAAP net loss of $1.65 billion (‑$0.29 per share) compared with net income of $410 million ($0.07 per share) a year earlier.
• 2026 guidance: adjusted EPS $2.80–$3.00 and revenue $59.5 billion–$62.5 billion, roughly flat year‑over‑year.
• Pfizer expects Covid product sales (vaccine and Paxlovid) to fall by about $1.5 billion year over year to approximately $5 billion in 2026.
• Another ~ $1.5 billion of expected 2026 revenue decline is tied to products losing market exclusivity, including increased competition for Prevnar.
• Pfizer is pursuing about $7.7 billion of cost reductions by end of 2027 through two separate initiatives.
• Pipeline push includes a $10 billion acquisition of Metsera; mid‑stage data show a once‑monthly obesity injection produced solid weight loss.

Background

Pfizer rose to prominence during the Covid‑19 pandemic with its mRNA vaccine and the antiviral Paxlovid; those products were major revenue drivers in 2021–2022. As the pandemic shifted into an endemic phase, global demand for repeated vaccination and antiviral courses has diminished, pushing companies to rebalance portfolios toward chronic and specialty medicines. Simultaneously, several of Pfizer’s high‑revenue legacy drugs have begun to face biosimilar or branded competition following patent expirations, compressing sales for products like Prevnar.

In late 2025, Pfizer signaled a more conservative 2026 revenue outlook tied to these twin headwinds—declining Covid sales and exclusivity losses—prompting investor caution. Management has argued the right response is a two‑pronged strategy: active cost reduction and targeted investments across the pipeline, including sizeable M&A aimed at entering growth categories such as obesity. Regulatory and pricing policy shifts, including a drug‑pricing agreement affecting Medicaid and Medicare pricing, also factor into the company’s near‑term margin assumptions.

Main event

For the quarter ended Dec. 31, 2025, Pfizer reported adjusted earnings per share of $0.66, above the $0.57 consensus compiled by LSEG, and revenue of $17.56 billion versus $16.95 billion expected. The company recorded a GAAP net loss of $1.65 billion, reflecting restructuring and other items; excluding those charges management presented the $0.66 adjusted EPS figure. Revenue was roughly 1% lower than the same period in 2024, primarily because of reduced Covid product volumes.

Pfizer reiterated its 2026 guidance range of $2.80–$3.00 adjusted EPS and revenue guidance of $59.5 billion–$62.5 billion, guidance the company calls modest and conservative given ongoing market dynamics. Management attributes about $1.5 billion of the anticipated 2026 revenue shortfall to lower Covid product sales (vaccine and Paxlovid combined) and another roughly $1.5 billion to expected losses of exclusivity on certain established products. The company said some of the revenue pressure will be offset over time by new product launches and pipeline progress.

On the pipeline front, Pfizer emphasized the recently announced $10 billion acquisition of Metsera, an obesity‑focused biotech. The company released mid‑stage data showing Metsera’s investigational monthly injectable produced meaningful weight loss in trials, a signal management presented as an important diversification away from Covid dependence. Separately, Pfizer is pursuing about $7.7 billion in cost savings by the end of 2027 across two initiatives designed to improve operating efficiency and offset margin pressure.

Analysis & implications

Pfizer’s ability to beat near‑term estimates while reaffirming conservative guidance underscores a transition phase: results still reflect residual Covid revenue but management is positioning the company for a post‑pandemic product mix. The adjusted EPS beat demonstrates operating resilience when non‑cash and restructuring items are stripped out, but the GAAP net loss highlights integration and one‑off costs linked to transformation efforts. Investors will weigh the tradeoff between short‑term earnings volatility and longer‑term return potential from pipeline bets.

The Metsera deal signals Pfizer’s strategic pivot into obesity, a market with sizable demand and competing entrants. Mid‑stage positive data are encouraging but do not guarantee regulatory approval or commercial success; pathway, pricing, and payer access will determine whether the acquisition meaningfully replaces Covid-era revenue. Commercial rollout timing, manufacturing scale‑up and competitive pressure (including oral and injectable obesity therapies from rivals) are key uncertainties.

Policy changes add another layer of complexity. Under a recent drug‑pricing agreement, Pfizer has committed to Medicaid pricing tied to the lowest price offered in other developed countries and set ‘most‑favored‑nation’ guarantees for new drugs across Medicare, Medicaid and commercial payers in exchange for a three‑year tariff exemption. That arrangement can compress margins and puts a premium on volume and cost discipline for new launches. Together, these items mean Pfizer’s near‑term profitability will depend on the speed of portfolio renewal and execution of planned cost reductions.

Comparison & data

The table places the quarter in context: adjusted EPS beat consensus while revenue was slightly down year‑over‑year. The GAAP net loss contrasts with a modest net income in Q4 2024, largely because of restructuring, intangible asset costs and other items excluded from adjusted results. Looking ahead, the guidance range for 2026 projects flat revenue versus 2025, reflecting anticipated declines in Covid sales and exclusivity losses offset partially by new products, M&A and cost savings.

Reactions & quotes

“There is price compression and margin compression baked into the 2026 guidance,”

Dave Denton, Pfizer CFO (Dec. 2025)

The CFO’s remark, made in December and reiterated around the results, explains management’s conservative margin assumptions tied to pricing commitments and deeper Medicaid discounts under the pricing agreement. Investors have treated that language as a signal the company expects near‑term margin pressure even if top‑line erosion stabilizes.

“Mid‑stage Metsera data show a monthly injectable produced solid weight loss,”

Pfizer (company data release)

Pfizer highlighted the Metsera data as validation for the acquisition thesis. Company materials framed the result as a step toward expanding into obesity therapeutics, but executives have not presented full pivotal timelines or commercial assumptions tied to that program in the Q4 release.

Unconfirmed

• Long‑term commercial uptake of Metsera’s monthly obesity injection: mid‑stage data are positive, but pivotal results, regulatory timing and payer coverage remain to be confirmed.
• Exact financial impact and mechanics of the three‑year tariff exemption tied to the drug‑pricing agreement require full regulatory documentation for confirmation.
• Precise magnitude and timing of the $7.7 billion in cost reductions depend on implementation details yet to be disclosed.

Bottom line

Pfizer’s Q4 performance shows resilience: adjusted earnings exceeded estimates and revenue marginally outperformed expectations despite falling Covid sales. Management is deliberately conservative about 2026, signaling that pricing commitments and exclusivity losses will constrain near‑term growth. The company’s strategy centers on reallocating capital—through M&A like Metsera, pipeline advancement and structural cost reductions—to generate new engines of growth beyond its pandemic portfolio.

For investors and industry observers, the critical watchpoints are execution on Metsera integration and its clinical program, progress on cost‑saving initiatives, how quickly new launches can scale, and the real‑world effects of the pricing agreement on margins and market access. Those elements will determine whether Pfizer can replace declining Covid revenue and restore sustained top‑line growth over the medium term.

Sources

• CNBC — News report on Pfizer Q4 results (news/media)
• Pfizer Investor Relations (official/company)